Protara Therapeutics, Inc. TARA
Protara Therapeutics, Inc. (Nasdaq: TARA) is an oncology drug developer. Its lead program, TARA-002 in NMIBC, is in Phase 2 for Non-muscle invasive bladder cancer (NMIBC), high-grade carcinoma in situ (CIS). Its next catalyst on record is TARA-002 in NMIBC (BCG-Unresponsive): Complete enrollment of BCG-Unresponsive registrational cohort (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: TARA-002 in NMIBC (BCG-Unresponsive) — Complete enrollment of BCG-Unresponsive registrational cohort (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| IV Choline Chloride | Choline deficiency in patients on long-term parenteral support | small molecule | Phase 3 |
| TARA-002 in NMIBC | BCG-Unresponsive CIS (± Ta/T1) | cell therapy | Phase 2 |
| TARA-002 in NMIBC | BCG-Naïve CIS | cell therapy | Phase 2 |
| TARA-002 in LMs | Macrocystic and mixed-cystic lymphatic malformations | cell therapy | Phase 2 |
Recent results and decisions
- Nov 6, 2026completed enrollment Protara completed enrollment of the Phase 2b portion of the THRIVE-3 trial evaluating IV Choline Chloride in patients on parenteral support.
Protara completed enrollment of the Phase 2b portion of the THRIVE-3 trial evaluating IV Choline Chloride in patients on PS.
Filing - Feb 23, 2026positive BCG-Unresponsive interim: CR 68.2% (15/22) at 6 months, 33.3% (5/15) at 12 months, 65.7% (23/35) at any time; no Grade 3+ treatment-related AEs.
The CR rate was 68.2% (15 of 22) at six months and 33.3% (5 of 15) at 12 months
Filing - Dec 3, 2025positive Updated interim in BCG-Naive NMIBC: CR at any time 72% (21/29), 69% (18/26) at 6 months, 50% (7/14) at 12 months; no Grade 3+ treatment-related AEs.
The CR rate at any time was 72% (21/29).
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.